Literature DB >> 8695044

Differential regional and kinetics effects of piribedil and bromocriptine on dopamine metabolites: a brain microdialysis study in freely moving rats.

R Pagliari1, L Peyrin, O Crambes.   

Abstract

Brain microdialysis coupled to HPLC was applied to freely moving rats to investigate the regional kinetics of piribedil and bromocriptine on the extracellular levels of 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) in striatum, nucleus accumbens, and frontal cortex. Both D2 agonists (20 mg/kg i.p.) decreased DOPAC and HVA in the three brain regions. The responsiveness of frontal cortex to both compounds was greater than those previously reported with other dopaminergic drugs. Regional and temporal differences were observed under piribedil: DOPAC and HVA levels decreased more in the nucleus accumbens than in striatum or frontal cortex but increased over basal values from the 5th hour in the frontal cortex suggesting a late stimulatory effect of piribedil on dopamine synthesis in this area. Such regional effects differentiate piribedil from most other D2 agonists and could explain some behavioural and therapeutic actions possibly related to involvement of nucleus accumbens or/and frontal cortex.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8695044     DOI: 10.1007/bf01271542

Source DB:  PubMed          Journal:  J Neural Transm Gen Sect


  47 in total

1.  Indications of piribedil in L-DOPA-treated parkinsonian patients: physiopathologic implications.

Authors:  P Rondot; N Bathien; J L Dumas
Journal:  Adv Neurol       Date:  1975

Review 2.  Dopaminergic insufficiency reflecting cerebral ageing: value of a dopaminergic agonist, piribedil.

Authors:  H Ollat
Journal:  J Neurol       Date:  1992       Impact factor: 4.849

3.  Effects of thioproperazine and apomorphine on dopamine synthesis in the mesocortical dopaminergic systems.

Authors:  B Scatton; A M Thierry; J Glowinski; L Julou
Journal:  Brain Res       Date:  1975-05-02       Impact factor: 3.252

Review 4.  Ergot drugs and central monoaminergic mechanisms: a histochemical, biochemical and behavioral analysis.

Authors:  K Fuxe; B B Fredholm; S O Ogren; L F Agnati; T Hökfelt; J A Gustafsson
Journal:  Fed Proc       Date:  1978-06

5.  Effects of piribedil on noradrenaline and MOPEG-SO4 levels in the rat brain.

Authors:  S Garattini; S R Bareggi; V Marc; G Calderini; P L Morselli
Journal:  Eur J Pharmacol       Date:  1974-09       Impact factor: 4.432

6.  ET495 and brain catecholamine mechanisms: evidence for stimulation of dopamine receptors.

Authors:  H Corrodi; L O Farnebo; K Fuxe; B Hamberger; U Ungerstedt
Journal:  Eur J Pharmacol       Date:  1972-11       Impact factor: 4.432

7.  Pramipexole, a dopamine D2 autoreceptor agonist, decreases the extracellular concentration of dopamine in vivo.

Authors:  A J Carter; R E Müller
Journal:  Eur J Pharmacol       Date:  1991-07-23       Impact factor: 4.432

8.  Behavioural, biochemical and electrophysiological studies on the motor depressant and stimulant effects of bromocriptine.

Authors:  D M Jackson; L P Martin; L G Larsson; R F Cox; B L Waszczak; S B Ross
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-09       Impact factor: 3.000

9.  A10 dopamine neurons: role of autoreceptors in determining firing rate and sensitivity to dopamine agonists.

Authors:  F J White; R Y Wang
Journal:  Life Sci       Date:  1984-03-19       Impact factor: 5.037

10.  Differential drug effects on dopamine concentrations and rates of turnover in the median eminence, olfactory tubercle and corpus striatum.

Authors:  G A Gudelsky; E K Moore
Journal:  J Neural Transm       Date:  1976       Impact factor: 3.575

View more
  2 in total

Review 1.  Persistent cognitive dysfunction after traumatic brain injury: A dopamine hypothesis.

Authors:  James W Bales; Amy K Wagner; Anthony E Kline; C Edward Dixon
Journal:  Neurosci Biobehav Rev       Date:  2009-04-01       Impact factor: 8.989

Review 2.  Access to the CNS: Biomarker Strategies for Dopaminergic Treatments.

Authors:  Willem Johan van den Brink; Semra Palic; Isabelle Köhler; Elizabeth Cunera Maria de Lange
Journal:  Pharm Res       Date:  2018-02-15       Impact factor: 4.200

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.